Bionomics

Bionomics is a global, clinical-stage biotechnology company specializing in the development of novel, first-in-class ion channel modulators aimed at treating serious central nervous system (CNS) disorders. Leveraging deep expertise in ion channel biology and translational medicine, Bionomics designs best-in-class oral small molecules to modulate ion channel function, influence neurotransmission and consequently downstream signaling in the brain.

Their lead asset, BNC210, is a small molecule with unique properties and a highly differentiated emerging profile, offering non-sedating, non-habit forming and non-cognition impairing anxiolytic and antidepressant effects. BNC210 is in late-stage development for the treatment of Social Anxiety Disorder (Phase 3) and Post-Traumatic Stress Disorder (Phase 3 start-up phase).

The company's research focuses on addressing unmet medical needs in neuropsychiatry, where traditional treatments often carry significant side effect burdens. By targeting specific ion channels in the brain, Bionomics aims to develop therapies that provide therapeutic benefit while minimizing adverse effects on cognition and daily functioning. This approach represents a mechanistically distinct pathway compared to conventional anxiolytics and antidepressants.